View Older Stories View More Recent Stories

Sep 11, 2018 12:00PM OSE Immunotherapeutics Announces Issuance of a European Patent Protecting FR104, CD28-Antagonist Immunotherapy
Sep 11, 2018 12:00PM OSE Immunotherapeutics Announces Issuance of a European Patent Protecting FR104, CD28-Antagonist Immunotherapy
Sep 6, 2018 12:00PM OSE Immunotherapeutics Reports First-Half 2018 Results and Provides a Corporate Update
Sep 6, 2018 12:00PM OSE Immunotherapeutics Reports First-Half 2018 Results and Provides a Corporate Update
Aug 22, 2018 12:00PM OSE Immunotherapeutics Publishes New Efficacy Data on FR104, CD28-Antagonist Immunotherapy
Aug 22, 2018 12:00PM OSE Immunotherapeutics Publishes New Efficacy Data on FR104, CD28-Antagonist Immunotherapy
Jul 5, 2018 12:00PM OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi®
Jul 5, 2018 12:00PM OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi®
Jul 2, 2018 02:00AM OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®
Jul 2, 2018 02:00AM OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®
Jun 13, 2018 12:00PM OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting
Jun 13, 2018 12:00PM OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting
May 17, 2018 12:00PM OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum
May 17, 2018 12:00PM OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum
May 7, 2018 02:00AM OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting
May 7, 2018 02:00AM OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas
Apr 23, 2018 12:00PM OSE Immunotherapeutics Receives the EuroNext Tech40 Label
Apr 23, 2018 12:00PM OSE Immunotherapeutics Receives the Euronext Tech40 Label
Apr 12, 2018 12:00PM OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management
Apr 12, 2018 12:00PM OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management
Apr 5, 2018 01:30AM OSE Immunotherapeutics to Host Conference Call on April 5, 2018 to Discuss Boehringer Ingelheim Global Immuno-Oncology Partnership
Apr 5, 2018 01:30AM OSE Immunotherapeutics to Host Conference Call on April 5, 2018 to Discuss Boehringer Ingelheim Global Immuno-Oncology Partnership
Mar 28, 2018 12:07PM OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products
Mar 28, 2018 12:00PM OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products
Mar 27, 2018 12:00PM OSE Immunotherapeutics Announces Participation At The H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
Mar 27, 2018 12:00PM OSE Immunotherapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
Mar 15, 2018 01:00PM OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor T
Mar 15, 2018 01:00PM OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor T
Feb 28, 2018 12:00PM OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING®
Feb 28, 2018 12:00PM OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING®
Feb 27, 2018 01:30AM OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Tre
Feb 27, 2018 01:30AM OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Tre
Jan 25, 2018 12:00PM OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Appli
Jan 25, 2018 12:00PM OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Appli
Jan 4, 2018 02:00AM OSE Immunotherapeutics to present at Biotech Showcase™ 2018 Conference
Jan 4, 2018 02:00AM OSE Immunotherapeutics to Present at Biotech Showcase™ 2018 Conference
Jan 3, 2018 02:00PM OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors
Jan 3, 2018 02:00PM OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors
Dec 19, 2017 02:00AM OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases
Dec 19, 2017 02:00AM OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases
Dec 14, 2017 12:00PM OSE Immunotherapeutics Receives a Grant From French Government Program “Fonds Unique Interministériel” to Explore New Cytotoxic Antibodies
Dec 14, 2017 12:00PM OSE Immunotherapeutics Receives a Grant from French Government Program “Fonds Unique Interministériel” to Explore New Cytotoxic Antibodies
Dec 7, 2017 01:30AM OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
Dec 7, 2017 01:30AM OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
Oct 26, 2017 12:00PM OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE®
Oct 26, 2017 12:00PM OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE®
Oct 19, 2017 12:00PM OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
Oct 2, 2017 12:00PM OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment
Sep 28, 2017 12:00PM OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells
Sep 28, 2017 12:00PM OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells
View More Recent Stories View Older Stories